These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 34696460)

  • 1. Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence.
    Tolksdorf B; Nie C; Niemeyer D; Röhrs V; Berg J; Lauster D; Adler JM; Haag R; Trimpert J; Kaufer B; Drosten C; Kurreck J
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA targeting the leader sequence of SARS-CoV inhibits virus replication.
    Li T; Zhang Y; Fu L; Yu C; Li X; Li Y; Zhang X; Rong Z; Wang Y; Ning H; Liang R; Chen W; Babiuk LA; Chang Z
    Gene Ther; 2005 May; 12(9):751-61. PubMed ID: 15772689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Tolksdorf B; Heinze J; Niemeyer D; Röhrs V; Berg J; Drosten C; Kurreck J
    Antiviral Res; 2024 Jun; 226():105879. PubMed ID: 38599550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SARS-CoV-2 Replication by Self-Assembled siRNA Nanoparticles Targeting Multiple Highly Conserved Viral Sequences.
    Sun J; Lu S; Xiao J; Xu N; Li Y; Xu J; Deng M; Xuanyuan H; Zhang Y; Wu F; Jin W; Liu K
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SARS-CoV replication by siRNA.
    Wu CJ; Huang HW; Liu CY; Hong CF; Chan YL
    Antiviral Res; 2005 Jan; 65(1):45-8. PubMed ID: 15652970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of the N-terminal region of nonstructural protein 1 in cis for SARS-CoV-2 defective RNA replication.
    Terasaki K; Makino S
    J Virol; 2024 Sep; 98(9):e0090024. PubMed ID: 39194239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.
    Ambike S; Cheng CC; Feuerherd M; Velkov S; Baldassi D; Afridi SQ; Porras-Gonzalez D; Wei X; Hagen P; Kneidinger N; Stoleriu MG; Grass V; Burgstaller G; Pichlmair A; Merkel OM; Ko C; Michler T
    Nucleic Acids Res; 2022 Jan; 50(1):333-349. PubMed ID: 34928377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs.
    Pfafenrot C; Schneider T; Müller C; Hung LH; Schreiner S; Ziebuhr J; Bindereif A
    Nucleic Acids Res; 2021 Dec; 49(21):12502-12516. PubMed ID: 34850109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
    Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells.
    Wang Z; Ren L; Zhao X; Hung T; Meng A; Wang J; Chen YG
    J Virol; 2004 Jul; 78(14):7523-7. PubMed ID: 15220426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.
    Yamasaki M; Saso W; Yamamoto T; Sato M; Takagi H; Hasegawa T; Kozakura Y; Yokoi H; Ohashi H; Tsuchimoto K; Hashimoto R; Fukushi S; Uda A; Muramatsu M; Takayama K; Maeda K; Takahashi Y; Nagase T; Watashi K
    Antiviral Res; 2024 Oct; 230():105992. PubMed ID: 39181215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.
    Rosenke K; Leventhal S; Moulton HM; Hatlevig S; Hawman D; Feldmann H; Stein DA
    J Antimicrob Chemother; 2021 Jan; 76(2):413-417. PubMed ID: 33164048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.
    Fahnøe U; Pham LV; Fernandez-Antunez C; Costa R; Rivera-Rangel LR; Galli A; Feng S; Mikkelsen LS; Gottwein JM; Scheel TKH; Ramirez S; Bukh J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion.
    Vora SM; Fontana P; Mao T; Leger V; Zhang Y; Fu TM; Lieberman J; Gehrke L; Shi M; Wang L; Iwasaki A; Wu H
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35149555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA.
    Ni B; Shi X; Li Y; Gao W; Wang X; Wu Y
    Antivir Ther; 2005; 10(4):527-33. PubMed ID: 16038478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi to treat SARS-CoV-2-variant proofing the next generation of therapies.
    McMillan NAJ; Morris KV; Idris A
    EMBO Mol Med; 2022 Apr; 14(4):e15811. PubMed ID: 35285158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2.
    Friedrich M; Pfeifer G; Binder S; Aigner A; Vollmer Barbosa P; Makert GR; Fertey J; Ulbert S; Bodem J; König EM; Geiger N; Schambach A; Schilling E; Buschmann T; Hauschildt S; Koehl U; Sewald K
    Front Bioeng Biotechnol; 2022; 10():801870. PubMed ID: 35309990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3.
    Dutkiewicz M; Grunert HP; Zeichhardt H; Lena SW; Wengel J; Kurreck J
    FEBS Lett; 2008 Sep; 582(20):3061-6. PubMed ID: 18691577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Activity of the Propylamylatin
    Brown AN; Strobel G; Hanrahan KC; Sears J
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.